Blood from Ebola patients who have survived infection has been used to treat patients actively fighting the virus. Now the Bill & Melinda Gates Foundation is backing efforts to test the efficacy of and scale up the production of convalescent plasma and other potential treatments in the field.
Two experimental antivirals are about to undergo snap clinical trials in Africa as doctors scramble to find an effective remedy for the lethal outbreak of Ebola. Doctors Without Borders says that it plans to launch studies of brincidofovir from Chimerix as well as Fujifilm's favipiravir.
Chimerix has outlined plans for a small Phase II study of its powerful antiviral brincidofovir as a counterpunch to Ebola.
Chimerix reports that its pilot Phase III study of the powerful antiviral brincidofovir has posted promising preliminary data, cutting the risk of death from lethal adenovirus infections by as much as half or more.
Back in March, Chimerix hustled to put together a small Phase III pilot program to test its closely watched antiviral brincidofovir for adenovirus infections. Today, CEO Michelle Berrey says the company is now scrambling to put together another overnight study plan for Ebola rather than risk getting hit with a fresh round of compassionate-use demands.
Colorado recently passed a "right to try" bill that allows people to use an experimental drug when the company agrees to give it, without federal approval, according to a report from NBC News. And now other states are beginning to discuss similar legislation, as The Goldwater Institute presses for such laws from coast to coast.
Just weeks after enduring a storm of controversy triggered by his initial refusal to provide a potent but experimental antiviral to a dying child under a compassionate use program, Chimerix CEO Ken Moch is out. The company announced that Moch had resigned--completely unexpectedly--to "pursue other interests" as the board introduced a new CEO to run the company.
Last week the parents of 7-year-old Josh Hardy managed to whip up a media tempest big enough to get the biotech Chimerix and the FDA to work out a pilot study so that their child could be treated after their compassionate use request was denied, alongside many others. Now the parents of another young boy afflicted by a terrible disease are using some interesting PR tactics in an attempt to achieve a much larger goal.
Chimerix will evidently have no trouble finding the 20 patients it is recruiting for the pilot study of its antiviral brincidofovir. And it still isn't willing to provide its therapy under the FDA's "compassionate use" regulations.
On Tuesday morning, Chimerix CEO Ken Moch was at the center of a media storm, maintaining that there was no way the biotech could responsibly provide its experimental antiviral to a dying child named Josh Hardy, a drug the boy's parents vowed was all that could save the child's life. By Tuesday night, though, Moch had found a way to give the treatment to the 7-year-old after all, as part of the clinical development program for the drug.